Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach

Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological...

Full description

Saved in:
Bibliographic Details
Published inActa pharmacologica Sinica Vol. 37; no. 7; pp. 963 - 972
Main Authors Qi, Quan, Li, Rui, Li, Hui-ying, Cao, Yu-bing, Bai, Ming, Fan, Xiao-jing, Wang, Shu-yan, Zhang, Bo, Li, Shao
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.07.2016
Nature Publishing Group
Subjects
Online AccessGet full text
ISSN1671-4083
1745-7254
1745-7254
DOI10.1038/aps.2016.53

Cover

Abstract Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti- tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SYSY and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is neuroblastoma and mouse colorectal cancer in vitro and in vivo, through dentified as an anti-tumor agent against human nhibiting the PI3K-AKT signaling pathways and IL-1 levels
AbstractList Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including “regulation of lipase activity”, “response to nicotine” and “regulation of cell proliferation”. Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro , and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro . Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo , through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.
Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti- tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SYSY and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is neuroblastoma and mouse colorectal cancer in vitro and in vivo, through dentified as an anti-tumor agent against human nhibiting the PI3K-AKT signaling pathways and IL-1 levels
Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.
Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.
Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms.AIMNuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms.The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments.METHODSThe pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments.The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells.RESULTSThe nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells.By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.CONCLUSIONBy using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.
Author Quan QI Rui LI Hui-ying LI Yu-bing CAO Ming BAI Xiao-jing FAN Shu-yan WANG Bo ZHANG Shao LI
AuthorAffiliation Tianjin State Key Laboratory of Modem Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China MOE Key Lab of Bioinformatics, Bioinformatics Division, TNLIST and Department of Automation, Tsinghua University, Beijing 100084, China The Second Hospital Affiliated to Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China Tianjin International Joint Academy of Biotechnology & Medicine, Tianjin 300457, China
Author_xml – sequence: 1
  givenname: Quan
  surname: Qi
  fullname: Qi, Quan
  organization: Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University
– sequence: 2
  givenname: Rui
  surname: Li
  fullname: Li, Rui
  organization: Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University
– sequence: 3
  givenname: Hui-ying
  surname: Li
  fullname: Li, Hui-ying
  organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University
– sequence: 4
  givenname: Yu-bing
  surname: Cao
  fullname: Cao, Yu-bing
  organization: Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine
– sequence: 5
  givenname: Ming
  surname: Bai
  fullname: Bai, Ming
  organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University
– sequence: 6
  givenname: Xiao-jing
  surname: Fan
  fullname: Fan, Xiao-jing
  organization: The Second Hospital Affiliated to Tianjin University of Traditional Chinese Medicine
– sequence: 7
  givenname: Shu-yan
  surname: Wang
  fullname: Wang, Shu-yan
  organization: Tianjin International Joint Academy of Biotechnology & Medicine
– sequence: 8
  givenname: Bo
  surname: Zhang
  fullname: Zhang, Bo
  email: z-b07@mails.tsinghua.edu.cn
  organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University, Tianjin International Joint Academy of Biotechnology & Medicine
– sequence: 9
  givenname: Shao
  surname: Li
  fullname: Li, Shao
  email: shaoli@mail.tsinghua.edu.cn
  organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27180984$$D View this record in MEDLINE/PubMed
BookMark eNqNkslv1DAUxiNURBc4cUcRXJAgg7d4uVRCFUulSlzgbL1xnIlLYqe2U9T_Hg8zjEoFEidbz7_v-XvLaXXkg7dV9RyjFUZUvoM5rQjCfNXSR9UJFqxtBGnZUblzgRuGJD2uTlO6RogSitWT6pgILJGS7KTyl5312fXOQHbB16Gv82BrKLEmL1OINZjsbl2-K7GunqwZwLs0pS3pF-N6G523RRTDshlqqL3NP0L8Xs8DxAlMGMOmaOc5BjDD0-pxD2Oyz_bnWfXt44evF5-bqy-fLi_eXzWmFSQ3neJSUbkG1REEneVSdGAUBd4C4R2lsqeYWsLXpiesl6zjtNQkeqyYsQToWXW-yzsv68l2ptQYYdRzdBPEOx3A6T9fvBv0JtxqpigVnJQEr_cJYrhZbMp6csnYcQRvw5J06Z_krcBY_g-KGS2wKuirB-h1WKIvndhSSCCMBC_Ui_vmD65_T60Ab3aAiSGlaPsDgpHe7oQuO6G3O6FbWmj8gDYu_5p2qdyN_9C83WlSyew3Nt4z-lf85f6LIfjNTVEcHHGuGMEUEfoTgSbV2g
CitedBy_id crossref_primary_10_3389_fphar_2018_00010
crossref_primary_10_1016_j_aca_2022_339772
crossref_primary_10_1016_j_apsusc_2023_158698
crossref_primary_10_1021_acs_jafc_0c04985
crossref_primary_10_3390_molecules23112899
crossref_primary_10_1186_s12986_021_00549_0
crossref_primary_10_1016_j_biopha_2023_115075
crossref_primary_10_1016_j_dib_2024_110962
crossref_primary_10_1155_2021_6665137
crossref_primary_10_3389_fonc_2022_838152
crossref_primary_10_3389_fphar_2021_613104
crossref_primary_10_1039_D2MO00158F
crossref_primary_10_1016_j_jep_2024_118262
crossref_primary_10_1016_j_crphys_2021_12_004
crossref_primary_10_1155_2021_1353674
crossref_primary_10_1093_hr_uhac276
crossref_primary_10_1016_j_csbj_2019_02_002
crossref_primary_10_1016_j_jep_2021_114335
crossref_primary_10_1360_SSV_2021_0369
crossref_primary_10_1038_s41598_022_07087_6
crossref_primary_10_3390_ijms22189819
crossref_primary_10_1016_j_euroneuro_2018_07_096
crossref_primary_10_1360_SSI_2021_0243
crossref_primary_10_1016_j_jff_2021_104682
crossref_primary_10_1002_pca_3108
crossref_primary_10_1007_s11101_024_09943_x
crossref_primary_10_1242_bio_060448
crossref_primary_10_3390_cancers14030529
crossref_primary_10_3390_plants12233923
crossref_primary_10_1016_j_canlet_2019_05_015
crossref_primary_10_1016_j_ejmech_2021_113857
crossref_primary_10_1186_s13046_019_1134_y
crossref_primary_10_3389_fphar_2017_00939
crossref_primary_10_1016_j_phrs_2023_106820
crossref_primary_10_1016_j_jare_2023_11_003
crossref_primary_10_2174_1568026623666230111154537
crossref_primary_10_1007_s40261_018_0683_8
crossref_primary_10_3390_cancers10110461
crossref_primary_10_3389_fbinf_2022_928116
crossref_primary_10_3390_life13040893
crossref_primary_10_1177_1934578X1701200849
crossref_primary_10_1620_tjem_254_17
crossref_primary_10_3389_fvets_2022_939377
crossref_primary_10_1038_aps_2017_210
crossref_primary_10_3389_fphar_2021_632236
crossref_primary_10_2139_ssrn_3914869
crossref_primary_10_1002_ptr_5732
crossref_primary_10_1016_j_jep_2020_113429
crossref_primary_10_1021_acs_jafc_4c04818
crossref_primary_10_1016_j_jafr_2024_101362
crossref_primary_10_1016_j_scib_2023_05_023
crossref_primary_10_1007_s11030_023_10791_8
crossref_primary_10_1016_j_phymed_2022_154536
crossref_primary_10_1016_j_semcancer_2019_12_010
crossref_primary_10_1080_10408398_2021_2009436
crossref_primary_10_1016_j_tifs_2021_04_033
crossref_primary_10_3390_ijms241914532
crossref_primary_10_1016_j_indcrop_2022_114694
crossref_primary_10_1155_2017_1583185
crossref_primary_10_1016_j_jep_2016_12_042
crossref_primary_10_1007_s11356_022_19249_0
crossref_primary_10_3389_fphar_2018_01514
crossref_primary_10_1016_j_phrs_2021_106002
Cites_doi 10.1093/nar/gki033
10.1073/pnas.1301814110
10.1002/pbc.20219
10.1038/nchembio.118
10.1021/jm0303711
10.2174/156800909789271521
10.1016/j.jep.2015.09.034
10.1093/nar/gkn923
10.1002/hep.27551
10.1007/BF00171991
10.1371/journal.pone.0011764
10.3390/molecules191117829
10.3724/SP.J.1009.2013.00110
10.1016/j.jep.2015.02.015
10.1016/S1044-579X(02)00014-7
10.1093/nar/gkn892
10.1038/75556
10.1056/NEJM199811053391901
10.1186/1471-2105-11-S11-S6
10.1142/S0192415X03001429
10.1021/ja00738a045
10.1055/s-0030-1250186
10.1038/nchembio.2007.53
10.1016/j.drudis.2008.02.001
10.1016/j.jep.2005.12.036
10.1093/nar/gkp896
10.1016/j.bmc.2012.11.038
10.3736/jcim20070501
10.1126/science.aab0642
10.1038/nchembio.216
ContentType Journal Article
Copyright CPS and SIMM 2016
Copyright Nature Publishing Group Jul 2016
Copyright © 2016 CPS and SIMM 2016 CPS and SIMM
Copyright_xml – notice: CPS and SIMM 2016
– notice: Copyright Nature Publishing Group Jul 2016
– notice: Copyright © 2016 CPS and SIMM 2016 CPS and SIMM
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7QR
7T5
7TK
7TO
7U9
7X7
7XB
88E
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7N
M7P
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/aps.2016.53
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Immunology Abstracts
Neurosciences Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database (ProQuest)
Biotechnology and BioEngineering Abstracts
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

AIDS and Cancer Research Abstracts
MEDLINE
MEDLINE - Academic
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach
EISSN 1745-7254
EndPage 972
ExternalDocumentID PMC4933762
4105333361
27180984
10_1038_aps_2016_53
669421302
Genre Journal Article
GroupedDBID ---
-05
-0E
-Q-
-S~
.3N
0R~
188
1OC
23M
2RA
2WC
31~
36B
3V.
4.4
406
53G
5GY
5VR
5VS
6J9
70F
7X7
8-1
88E
8FI
8FJ
8R4
8R5
8RM
92L
92M
9D9
9DE
A8Z
AADWK
AANZL
AATNV
AAWBL
AAYFA
AAYJO
AAZLF
ABAWZ
ABGIJ
ABKZE
ABUWG
ACAOD
ACBMV
ACBRV
ACBYP
ACGFO
ACGFS
ACIGE
ACIWK
ACKTT
ACPRK
ACRQY
ACTTH
ACVWB
ACXQS
ACZOJ
ADBBV
ADFRT
ADHDB
ADMDM
ADQMX
ADRAZ
ADYYL
AEDAW
AEFTE
AEJRE
AENEX
AESKC
AEVLU
AEXYK
AFBPY
AFKRA
AFNRJ
AFRAH
AFSHS
AFUIB
AFZJQ
AGAYW
AGEZK
AGGBP
AGHAI
AHMBA
AHSBF
AILAN
AJAOE
AJCLW
AJDOV
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMRJV
AMYLF
AOIJS
AXYYD
BAWUL
BBNVY
BENPR
BFHJK
BHPHI
BKKNO
BPHCQ
BVXVI
C1A
CAG
CAJEE
CAJUS
CCEZO
CCPQU
CHBEP
CIEJG
CO8
COF
CQIGP
CS3
CW9
DIK
DNIVK
DPUIP
E3Z
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMOBN
ESTFP
F5P
FA0
FDQFY
FERAY
FIZPM
FSGXE
FYUFA
GX1
HCIFZ
HH5
HMCUK
HYE
HZI
HZ~
IWAJR
JSO
JUIAU
JZLTJ
K97
KQ8
LH4
LW6
M1P
M48
M7P
MK0
NQJWS
NXXTH
NYICJ
O9-
OK1
OVD
P2P
P6G
PQQKQ
PROAC
PSQYO
Q--
Q-4
Q2X
R-E
RNT
RNTTT
RPM
RT5
S..
SNX
SNYQT
SOHCF
SRMVM
SV3
SWTZT
T8U
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
U1F
U1G
U5E
U5O
UKHRP
UZ5
W91
~88
~NG
~WA
-SE
AACDK
AASML
AAXDM
ABAKF
ABZZP
ACMJI
AEFQL
AEMSY
AFBBN
AGQEE
AIGIU
ALIPV
FIGPU
LGEZI
LOTEE
NADUK
ROL
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
SOJ
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7QP
7QR
7T5
7TK
7TO
7U9
7XB
8FD
8FE
8FH
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
LK8
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
PUEGO
7X8
5PM
ID FETCH-LOGICAL-c572t-d968938ba9d20ade687dac93a65a26d338f313e26bcf24f84d632717f194ce2a3
IEDL.DBID M48
ISSN 1671-4083
1745-7254
IngestDate Thu Aug 21 17:52:03 EDT 2025
Fri Sep 05 05:47:55 EDT 2025
Fri Sep 05 12:27:11 EDT 2025
Sat Aug 23 14:49:31 EDT 2025
Mon Jul 21 06:03:23 EDT 2025
Tue Jul 01 02:18:33 EDT 2025
Thu Apr 24 23:10:56 EDT 2025
Fri Feb 21 02:40:29 EST 2025
Wed Feb 14 10:17:43 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords nuciferine
colorectal cancer
IL-1
neuroblastoma
drugCIPHER
TCM network pharmacology
anti-tumor agent
PI3K-AKT
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c572t-d968938ba9d20ade687dac93a65a26d338f313e26bcf24f84d632717f194ce2a3
Notes Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti- tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SYSY and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is neuroblastoma and mouse colorectal cancer in vitro and in vivo, through dentified as an anti-tumor agent against human nhibiting the PI3K-AKT signaling pathways and IL-1 levels
nuciferine; TCM network pharmacology; anti-tumor agent; neuroblastoma; colorectal cancer; PI3K-AKT; IL-1; drugClPHER
31-1347/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These two authors contributed equally to this work.
OpenAccessLink https://www.nature.com/articles/aps201653.pdf
PMID 27180984
PQID 1800701076
PQPubID 28815
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4933762
proquest_miscellaneous_1808657118
proquest_miscellaneous_1801436579
proquest_journals_1800701076
pubmed_primary_27180984
crossref_primary_10_1038_aps_2016_53
crossref_citationtrail_10_1038_aps_2016_53
springer_journals_10_1038_aps_2016_53
chongqing_primary_669421302
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-07-01
PublicationDateYYYYMMDD 2016-07-01
PublicationDate_xml – month: 07
  year: 2016
  text: 2016-07-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
– name: Shanghai
PublicationTitle Acta pharmacologica Sinica
PublicationTitleAbbrev Acta Pharmacol Sin
PublicationTitleAlternate Acta Pharmacologica Sinica
PublicationYear 2016
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Liu, Yi, Guo, Xiang, Deng, He (CR17) 2015; 165
Zhao, Li (CR12) 2010; 5
Ohlson (CR5) 2008; 13
Li, Zhang (CR8) 2013; 11
Hsiao, Liu (CR6) 2010; 76
Nakamura, Nakashima, Tanabe, Oda, Yokota, Fujimoto (CR16) 2013; 21
Huang da, Sherman, Lempicki (CR22) 2009; 37
Ashburner, Ball, Blake, Botstein, Butler, Cherry (CR27) 2000; 25
Wu, Wang, Weng, Yen (CR36) 2003; 31
Li, Zhang, Jiang, Wei, Zhang (CR13) 2010; 11
Fulda (CR31) 2009; 9
Wu, Wu (CR10) 2015; 13
Soignet, Maslak, Wang, Jhanwar, Calleja, Dardashti (CR2) 1998; 339
Young, Bender, Hoyt, McWhinnie, Chirn, Tao (CR34) 2008; 4
Zhang, Liu, Zhao, Wang, Liu, Li (CR14) 2013; 2013
Su, Luo, Zhu, Fu, Zhao, Chen (CR33) 2015; 61
Apte, Voronov (CR32) 2002; 12
Kanehisa, Goto, Furumichi, Tanabe, Hirakawa (CR23) 2010; 38
Rix, Superti-Furga (CR26) 2009; 5
Hopkins (CR7) 2008; 4
Li (CR11) 2015; 350
Bai, Xu, Chen, Liu, Gu, Wang (CR4) 2013; 110
Knight, Goodman, Taylor, Macdonald, Coltman, Constanzi (CR20) 1990; 8
Pritchard, Cotterill, Germond, Imeson, de Kraker, Jones (CR19) 2005; 44
Zhang, Wang, Li (CR21) 2013; 2013
Zhang, Xiao, Xu, Zhou, Zhou, Wang (CR37) 2006; 24
Ono, Hattori, Fukaya, Imai, Ohizumi (CR35) 2006; 106
Liu, Kao, Wu, Li, Huang, Li (CR18) 2014; 19
Hamosh, Scott, Amberger, Bocchini, McKusick (CR28) 2005; 33
Keshava Prasad, Goel, Kandasamy, Keerthikumar, Kumar, Mathivanan (CR24) 2009; 37
Posner, McRiner, Paik, Sur, Borstnik, Xie (CR1) 2004; 47
Taubes (CR25) 2012; 335
Meng, Liu (CR38) 2014; 35
Zhang, Lu, Bai, He, Tan, Bian (CR15) 2015; 175
Wani, Taylor, Wall, Coggon, McPhail (CR3) 1971; 93
Li (CR9) 2007; 5
Lin, Hou, Jin, Yu, Yang (CR30) 2008; 13
Tu, Li, Yang, Zou (CR29) 2001; 13
XM Wu (BFaps201653_CR10) 2015; 13
U Rix (BFaps201653_CR26) 2009; 5
F Bai (BFaps201653_CR4) 2013; 110
M Kanehisa (BFaps201653_CR23) 2010; 38
CM Liu (BFaps201653_CR18) 2014; 19
WL Hsiao (BFaps201653_CR6) 2010; 76
S Li (BFaps201653_CR13) 2010; 11
S Nakamura (BFaps201653_CR16) 2013; 21
S Li (BFaps201653_CR9) 2007; 5
B Zhang (BFaps201653_CR21) 2013; 2013
W Liu (BFaps201653_CR17) 2015; 165
B Su (BFaps201653_CR33) 2015; 61
S Fulda (BFaps201653_CR31) 2009; 9
Y Ono (BFaps201653_CR35) 2006; 106
J Zhang (BFaps201653_CR37) 2006; 24
MC Wani (BFaps201653_CR3) 1971; 93
DW Young (BFaps201653_CR34) 2008; 4
TS Keshava Prasad (BFaps201653_CR24) 2009; 37
G Taubes (BFaps201653_CR25) 2012; 335
S Lin (BFaps201653_CR30) 2008; 13
MJ Wu (BFaps201653_CR36) 2003; 31
SL Soignet (BFaps201653_CR2) 1998; 339
X Meng (BFaps201653_CR38) 2014; 35
B Zhang (BFaps201653_CR15) 2015; 175
GH Posner (BFaps201653_CR1) 2004; 47
CC Tu (BFaps201653_CR29) 2001; 13
S Zhao (BFaps201653_CR12) 2010; 5
S Li (BFaps201653_CR8) 2013; 11
M Ashburner (BFaps201653_CR27) 2000; 25
A Hamosh (BFaps201653_CR28) 2005; 33
W Huang da (BFaps201653_CR22) 2009; 37
RN Apte (BFaps201653_CR32) 2002; 12
J Pritchard (BFaps201653_CR19) 2005; 44
S Li (BFaps201653_CR11) 2015; 350
S Ohlson (BFaps201653_CR5) 2008; 13
B Zhang (BFaps201653_CR14) 2013; 2013
WA Knight (BFaps201653_CR20) 1990; 8
AL Hopkins (BFaps201653_CR7) 2008; 4
14971910 - J Med Chem. 2004 Feb 26;47(5):1299-301
19754357 - Curr Cancer Drug Targets. 2009 Sep;9(6):729-37
23270663 - Bioorg Med Chem. 2013 Feb 1;21(3):779-87
23787177 - Chin J Nat Med. 2013 Mar;11(2):110-20
18936753 - Nat Chem Biol. 2008 Nov;4(11):682-90
23440190 - Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4273-8
19033363 - Nucleic Acids Res. 2009 Jan;37(1):1-13
20635308 - Planta Med. 2010 Aug;76(11):1118-31
19690537 - Nat Chem Biol. 2009 Sep;5(9):616-24
21172056 - BMC Bioinformatics. 2010 Dec 14;11 Suppl 11:S6
25660283 - Chin J Nat Med. 2015 Jan;13(1):1-2
23653662 - Evid Based Complement Alternat Med. 2013;2013:456747
22223787 - Science. 2012 Jan 6;335(6064):28, 30-2
26435225 - J Ethnopharmacol. 2015 Dec 4;175:638-47
23476684 - Evid Based Complement Alternat Med. 2013;2013:278405
25294684 - Hepatology. 2015 Feb;61(2):585-97
18988627 - Nucleic Acids Res. 2009 Jan;37(Database issue):D767-72
5553076 - J Am Chem Soc. 1971 May 5;93(9):2325-7
9801394 - N Engl J Med. 1998 Nov 5;339(19):1341-8
20668676 - PLoS One. 2010 Jul 26;5(7):e11764
16495025 - J Ethnopharmacol. 2006 Jun 30;106(2):238-44
15546135 - Pediatr Blood Cancer. 2005 Apr;44(4):348-57
18468561 - Drug Discov Today. 2008 May;13(9-10):433-9
18066055 - Nat Chem Biol. 2008 Jan;4(1):59-68
17854545 - Zhong Xi Yi Jie He Xue Bao. 2007 Sep;5(5):489-93
10802651 - Nat Genet. 2000 May;25(1):25-9
25372397 - Molecules. 2014 Nov 03;19(11):17829-38
14696672 - Am J Chin Med. 2003;31(5):687-98
2380020 - Invest New Drugs. 1990;8 Suppl 1:S87-9
25698245 - J Ethnopharmacol. 2015 May 13;165:83-93
12147202 - Semin Cancer Biol. 2002 Aug;12(4):277-90
15608251 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D514-7
19880382 - Nucleic Acids Res. 2010 Jan;38(Database issue):D355-60
References_xml – volume: 33
  start-page: D514
  year: 2005
  end-page: 7
  ident: CR28
  article-title: Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gki033
– volume: 110
  start-page: 4273
  year: 2013
  end-page: 8
  ident: CR4
  article-title: Free energy landscape for the binding process of Huperzine A to acetylcholinesterase
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1301814110
– volume: 24
  start-page: 759
  year: 2006
  end-page: 61
  ident: CR37
  article-title: The research of nuciferin's antiarrhythmic effect
  publication-title: Herald Med
– volume: 44
  start-page: 348
  year: 2005
  end-page: 57
  ident: CR19
  article-title: High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.20219
– volume: 4
  start-page: 682
  year: 2008
  end-page: 90
  ident: CR7
  article-title: Network pharmacology: the next paradigm in drug discovery
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.118
– volume: 47
  start-page: 1299
  year: 2004
  end-page: 301
  ident: CR1
  article-title: Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents
  publication-title: J Med Chem
  doi: 10.1021/jm0303711
– volume: 9
  start-page: 729
  year: 2009
  end-page: 37
  ident: CR31
  article-title: The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800909789271521
– volume: 175
  start-page: 638
  year: 2015
  end-page: 47
  ident: CR15
  article-title: Tetramethylpyrazine identified by a network pharmacology approach ameliorates methotrexate-induced oxidative organ injury
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2015.09.034
– volume: 37
  start-page: 1
  year: 2009
  end-page: 13
  ident: CR22
  article-title: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkn923
– volume: 2013
  start-page: 456747
  year: 2013
  ident: CR21
  article-title: An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin
  publication-title: Evid Based Complement Alternat Med
– volume: 61
  start-page: 585
  year: 2015
  end-page: 97
  ident: CR33
  article-title: Interleukin-1β/IRAK-1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis
  publication-title: Hepatology
  doi: 10.1002/hep.27551
– volume: 8
  start-page: S87
  year: 1990
  end-page: 9
  ident: CR20
  article-title: Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group study
  publication-title: Invest New Drugs
  doi: 10.1007/BF00171991
– volume: 5
  start-page: e 11764
  year: 2010
  ident: CR12
  article-title: Network-based relating pharmacological and genomic spaces for drug target identification
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0011764
– volume: 35
  start-page: 119
  year: 2014
  end-page: 24
  ident: CR38
  article-title: Inhibitory effect of tea polyphenols on Caco-2 cells and their synergistic antioxidant activity with nuciferine
  publication-title: Food Sci
– volume: 19
  start-page: 17829
  year: 2014
  end-page: 38
  ident: CR18
  article-title: Antioxidant and anticancer aporphine alkaloids from the leaves of Gaertn. cv. Rosa-plena
  publication-title: Molecules
  doi: 10.3390/molecules191117829
– volume: 11
  start-page: 110
  year: 2013
  end-page: 20
  ident: CR8
  article-title: Traditional Chinese medicine network pharmacology: theory, methodology and application
  publication-title: Chin J Nat Med
  doi: 10.3724/SP.J.1009.2013.00110
– volume: 2013
  start-page: 278405
  year: 2013
  ident: CR14
  article-title: Vitexicarpin acts as a novel angiogenesis inhibitor and its target network
  publication-title: Evid Based Complement Alternat Med
– volume: 165
  start-page: 83
  year: 2015
  end-page: 93
  ident: CR17
  article-title: Nuciferine, extracted from Gaertn, inhibits tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2015.02.015
– volume: 12
  start-page: 277
  year: 2002
  end-page: 90
  ident: CR32
  article-title: Interleukin-1--a major pleiotropic cytokine in tumor-host interactions
  publication-title: Semin Cancer Biol
  doi: 10.1016/S1044-579X(02)00014-7
– volume: 37
  start-page: D767
  year: 2009
  end-page: 72
  ident: CR24
  article-title: Human protein reference database — 2009 update
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkn892
– volume: 25
  start-page: 25
  year: 2000
  end-page: 9
  ident: CR27
  article-title: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium
  publication-title: Nat Genet
  doi: 10.1038/75556
– volume: 339
  start-page: 1341
  year: 1998
  end-page: 8
  ident: CR2
  article-title: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199811053391901
– volume: 11
  start-page: S6
  year: 2010
  ident: CR13
  article-title: Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae
  publication-title: BMC Bioinformatics
  doi: 10.1186/1471-2105-11-S11-S6
– volume: 31
  start-page: 687
  year: 2003
  end-page: 98
  ident: CR36
  article-title: Antioxidant activity of methanol extract of the lotus leaf ( Gertn)
  publication-title: Am J Chin Med
  doi: 10.1142/S0192415X03001429
– volume: 93
  start-page: 2325
  year: 1971
  end-page: 7
  ident: CR3
  article-title: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from
  publication-title: J Am Chem Soc
  doi: 10.1021/ja00738a045
– volume: 76
  start-page: 1118
  year: 2010
  end-page: 31
  ident: CR6
  article-title: The role of traditional Chinese herbal medicines in cancer therapy--from TCM theory to mechanistic insights
  publication-title: Planta Med
  doi: 10.1055/s-0030-1250186
– volume: 4
  start-page: 59
  year: 2008
  end-page: 68
  ident: CR34
  article-title: Integrating high-content screening and ligand-target prediction to identify mechanism of action
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.2007.53
– volume: 13
  start-page: 138
  year: 2008
  end-page: 43
  ident: CR30
  article-title: Natural compound nuciferine activates chloride channel of wild type and F508 mutant cystic fibrosis transmembrane conductance regulator
  publication-title: Chin J Clin Pharmacol Ther
– volume: 13
  start-page: 433
  year: 2008
  end-page: 9
  ident: CR5
  article-title: Designing transient binding drugs: a new concept for drug discovery
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2008.02.001
– volume: 106
  start-page: 238
  year: 2006
  end-page: 44
  ident: CR35
  article-title: Anti-obesity effect of leaves extract in mice and rats
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2005.12.036
– volume: 38
  start-page: D355
  year: 2010
  end-page: 60
  ident: CR23
  article-title: KEGG for representation and analysis of molecular networks involving diseases and drugs
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkp896
– volume: 21
  start-page: 779
  year: 2013
  end-page: 87
  ident: CR16
  article-title: Alkaloid constituents from flower buds and leaves of sacred lotus ( , Nymphaeaceae) with melanogenesis inhibitory activity in B16 melanoma cells
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2012.11.038
– volume: 5
  start-page: 489
  year: 2007
  end-page: 93
  ident: CR9
  article-title: Framework and practice of network-based studies for Chinese herbal formula
  publication-title: Zhong Xi Yi Jie He Xue Bao
  doi: 10.3736/jcim20070501
– volume: 13
  start-page: 120
  year: 2001
  end-page: 1
  ident: CR29
  article-title: Experimental study of lotus leaf alkaloids role in weight loss in obese rats with hyperlipidemia
  publication-title: J JiangXi Coll Tradit Chin Med
– volume: 350
  start-page: S72
  year: 2015
  end-page: 4
  ident: CR11
  article-title: Mapping ancient remedies: applying a network approach to traditional Chinese medicine
  publication-title: Science
  doi: 10.1126/science.aab0642
– volume: 335
  start-page: 30
  year: 2012
  end-page: 2
  ident: CR25
  article-title: Cancer research. Unraveling the obesity — cancer connection
  publication-title: Science
– volume: 5
  start-page: 616
  year: 2009
  end-page: 24
  ident: CR26
  article-title: Target profiling of small molecules by chemical proteomics
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.216
– volume: 13
  start-page: 1
  year: 2015
  end-page: 2
  ident: CR10
  article-title: Network pharmacology: a new approach to unveiling Traditional Chinese medicine
  publication-title: Chin J Nat Med
– volume: 110
  start-page: 4273
  year: 2013
  ident: BFaps201653_CR4
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1301814110
– volume: 11
  start-page: 110
  year: 2013
  ident: BFaps201653_CR8
  publication-title: Chin J Nat Med
  doi: 10.3724/SP.J.1009.2013.00110
– volume: 175
  start-page: 638
  year: 2015
  ident: BFaps201653_CR15
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2015.09.034
– volume: 165
  start-page: 83
  year: 2015
  ident: BFaps201653_CR17
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2015.02.015
– volume: 13
  start-page: 120
  year: 2001
  ident: BFaps201653_CR29
  publication-title: J JiangXi Coll Tradit Chin Med
– volume: 93
  start-page: 2325
  year: 1971
  ident: BFaps201653_CR3
  publication-title: J Am Chem Soc
  doi: 10.1021/ja00738a045
– volume: 5
  start-page: 489
  year: 2007
  ident: BFaps201653_CR9
  publication-title: Zhong Xi Yi Jie He Xue Bao
  doi: 10.3736/jcim20070501
– volume: 8
  start-page: S87
  year: 1990
  ident: BFaps201653_CR20
  publication-title: Invest New Drugs
  doi: 10.1007/BF00171991
– volume: 2013
  start-page: 278405
  year: 2013
  ident: BFaps201653_CR14
  publication-title: Evid Based Complement Alternat Med
– volume: 335
  start-page: 30
  year: 2012
  ident: BFaps201653_CR25
  publication-title: Science
– volume: 31
  start-page: 687
  year: 2003
  ident: BFaps201653_CR36
  publication-title: Am J Chin Med
  doi: 10.1142/S0192415X03001429
– volume: 5
  start-page: e 11764
  year: 2010
  ident: BFaps201653_CR12
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0011764
– volume: 350
  start-page: S72
  year: 2015
  ident: BFaps201653_CR11
  publication-title: Science
  doi: 10.1126/science.aab0642
– volume: 19
  start-page: 17829
  year: 2014
  ident: BFaps201653_CR18
  publication-title: Molecules
  doi: 10.3390/molecules191117829
– volume: 44
  start-page: 348
  year: 2005
  ident: BFaps201653_CR19
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.20219
– volume: 4
  start-page: 59
  year: 2008
  ident: BFaps201653_CR34
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.2007.53
– volume: 9
  start-page: 729
  year: 2009
  ident: BFaps201653_CR31
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800909789271521
– volume: 13
  start-page: 138
  year: 2008
  ident: BFaps201653_CR30
  publication-title: Chin J Clin Pharmacol Ther
– volume: 13
  start-page: 433
  year: 2008
  ident: BFaps201653_CR5
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2008.02.001
– volume: 61
  start-page: 585
  year: 2015
  ident: BFaps201653_CR33
  publication-title: Hepatology
  doi: 10.1002/hep.27551
– volume: 47
  start-page: 1299
  year: 2004
  ident: BFaps201653_CR1
  publication-title: J Med Chem
  doi: 10.1021/jm0303711
– volume: 13
  start-page: 1
  year: 2015
  ident: BFaps201653_CR10
  publication-title: Chin J Nat Med
– volume: 76
  start-page: 1118
  year: 2010
  ident: BFaps201653_CR6
  publication-title: Planta Med
  doi: 10.1055/s-0030-1250186
– volume: 38
  start-page: D355
  year: 2010
  ident: BFaps201653_CR23
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkp896
– volume: 2013
  start-page: 456747
  year: 2013
  ident: BFaps201653_CR21
  publication-title: Evid Based Complement Alternat Med
– volume: 21
  start-page: 779
  year: 2013
  ident: BFaps201653_CR16
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2012.11.038
– volume: 37
  start-page: D767
  year: 2009
  ident: BFaps201653_CR24
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkn892
– volume: 106
  start-page: 238
  year: 2006
  ident: BFaps201653_CR35
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2005.12.036
– volume: 24
  start-page: 759
  year: 2006
  ident: BFaps201653_CR37
  publication-title: Herald Med
– volume: 25
  start-page: 25
  year: 2000
  ident: BFaps201653_CR27
  publication-title: Nat Genet
  doi: 10.1038/75556
– volume: 35
  start-page: 119
  year: 2014
  ident: BFaps201653_CR38
  publication-title: Food Sci
– volume: 37
  start-page: 1
  year: 2009
  ident: BFaps201653_CR22
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkn923
– volume: 12
  start-page: 277
  year: 2002
  ident: BFaps201653_CR32
  publication-title: Semin Cancer Biol
  doi: 10.1016/S1044-579X(02)00014-7
– volume: 5
  start-page: 616
  year: 2009
  ident: BFaps201653_CR26
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.216
– volume: 339
  start-page: 1341
  year: 1998
  ident: BFaps201653_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199811053391901
– volume: 4
  start-page: 682
  year: 2008
  ident: BFaps201653_CR7
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.118
– volume: 11
  start-page: S6
  year: 2010
  ident: BFaps201653_CR13
  publication-title: BMC Bioinformatics
  doi: 10.1186/1471-2105-11-S11-S6
– volume: 33
  start-page: D514
  year: 2005
  ident: BFaps201653_CR28
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gki033
– reference: 19880382 - Nucleic Acids Res. 2010 Jan;38(Database issue):D355-60
– reference: 2380020 - Invest New Drugs. 1990;8 Suppl 1:S87-9
– reference: 18988627 - Nucleic Acids Res. 2009 Jan;37(Database issue):D767-72
– reference: 23787177 - Chin J Nat Med. 2013 Mar;11(2):110-20
– reference: 19754357 - Curr Cancer Drug Targets. 2009 Sep;9(6):729-37
– reference: 23653662 - Evid Based Complement Alternat Med. 2013;2013:456747
– reference: 26435225 - J Ethnopharmacol. 2015 Dec 4;175:638-47
– reference: 25660283 - Chin J Nat Med. 2015 Jan;13(1):1-2
– reference: 15608251 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D514-7
– reference: 18936753 - Nat Chem Biol. 2008 Nov;4(11):682-90
– reference: 22223787 - Science. 2012 Jan 6;335(6064):28, 30-2
– reference: 25698245 - J Ethnopharmacol. 2015 May 13;165:83-93
– reference: 23440190 - Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4273-8
– reference: 9801394 - N Engl J Med. 1998 Nov 5;339(19):1341-8
– reference: 19690537 - Nat Chem Biol. 2009 Sep;5(9):616-24
– reference: 18066055 - Nat Chem Biol. 2008 Jan;4(1):59-68
– reference: 16495025 - J Ethnopharmacol. 2006 Jun 30;106(2):238-44
– reference: 21172056 - BMC Bioinformatics. 2010 Dec 14;11 Suppl 11:S6
– reference: 25372397 - Molecules. 2014 Nov 03;19(11):17829-38
– reference: 15546135 - Pediatr Blood Cancer. 2005 Apr;44(4):348-57
– reference: 19033363 - Nucleic Acids Res. 2009 Jan;37(1):1-13
– reference: 14971910 - J Med Chem. 2004 Feb 26;47(5):1299-301
– reference: 10802651 - Nat Genet. 2000 May;25(1):25-9
– reference: 5553076 - J Am Chem Soc. 1971 May 5;93(9):2325-7
– reference: 14696672 - Am J Chin Med. 2003;31(5):687-98
– reference: 23270663 - Bioorg Med Chem. 2013 Feb 1;21(3):779-87
– reference: 17854545 - Zhong Xi Yi Jie He Xue Bao. 2007 Sep;5(5):489-93
– reference: 12147202 - Semin Cancer Biol. 2002 Aug;12(4):277-90
– reference: 20635308 - Planta Med. 2010 Aug;76(11):1118-31
– reference: 23476684 - Evid Based Complement Alternat Med. 2013;2013:278405
– reference: 18468561 - Drug Discov Today. 2008 May;13(9-10):433-9
– reference: 25294684 - Hepatology. 2015 Feb;61(2):585-97
– reference: 20668676 - PLoS One. 2010 Jul 26;5(7):e11764
SSID ssj0032319
Score 2.3928244
Snippet Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used...
Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used...
Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a...
Aim:Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a...
Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 963
SubjectTerms Animals
Antineoplastic Agents - pharmacology
Aporphines - pharmacology
Biomedical and Life Sciences
Biomedicine
Cell Line, Tumor
Cell Survival - drug effects
Cluster Analysis
Drugs, Chinese Herbal - pharmacology
Humans
Immunology
Internal Medicine
Medical Microbiology
Mice
Mice, Nude
Neoplasm Invasiveness
Original
original-article
Pharmacology/Toxicology
Phosphatidylinositol 3-Kinases - metabolism
Signal Transduction - drug effects
Vaccine
Xenograft Model Antitumor Assays
医药网络
抗肿瘤活性
机制
活性鉴定
生物碱
神经母细胞瘤
药理学
荷叶
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwELZaemgvVd9NociVKIeKlCR2_DhVCIFQDxUHkPZmeW2nXYlNFrJ74N93JnGybLfimozy8Iw933g83xBykLMK_BiXac6CTrn0KrUuiJQLzwBwWO5dx_b5S1xc85-TchI33Np4rHJYE7uF2jcO98iPc4XMNBCsiB-L2xS7RmF2NbbQeEqeddRlYM9yMgZcDLALwt9cSIyTFIv1eRlTx3aBXN25-I5dkZ_DSlP_vgVfsemdtiDn9snJf9KnnVc6f0VeRjhJT3r9vyZPQv2GHF72fNT3R_RqXV7VHtFDerlmqr5_S-q-TLeK-3a0qSjgQQqDPUuXq3lzR7HsAbtLwDVP5wHLhGftvEXJeuXwWAygVBqb_VBL6_5UOV08eA8deMvfkevzs6vTizQ2YEhdKYtl6rUAOKOmVvsisz4IJb11mllR2gKUyVQFCg2FmLqq4JXiXrAC4sMq1xwbjbH3ZKdu6vCR0NILrWFxVQFCoKDwmVklhatcYN6yLCG7oxLMoifaMEJoXmBmNSHfBrUYF7nLsYXGjely6EwZ0KdBfZqSJeRgFB6e9F-xvUG_Js7b1qytLCFfxtsw4zCNYuvQrDoZAJmilPpRGQUSEL0l5ENvMuO3wAipTCueELlhTKMAMn5v3qlnfzrmb64ZOAQYjq-D2T349O1f_PT4L-6SFyjYHz7eIzvLu1X4DBBrOd3v5tFfkTcoLQ
  priority: 102
  providerName: ProQuest
Title Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach
URI http://lib.cqvip.com/qk/95561A/201607/669421302.html
https://link.springer.com/article/10.1038/aps.2016.53
https://www.ncbi.nlm.nih.gov/pubmed/27180984
https://www.proquest.com/docview/1800701076
https://www.proquest.com/docview/1801436579
https://www.proquest.com/docview/1808657118
https://pubmed.ncbi.nlm.nih.gov/PMC4933762
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEB7yuPRS-q6axGwhzaFEqaVdrXYPpcQlJhRqTInBN7HWrhJDLDt-QP3vM6NX4jjkZPCOZXlm1vONZucbgOOAZxjHROwH3GlfxFb5JnXSF9JyBBxG2LRg--zJy4H4M4yGO1AP46wUuHg2taN5UoP57dn_u_Uv3PA_y5Zx9cPMiHc7kGcR34V9DEmSsrC_oikncAQxhINxgRImxatGvScfJnqFm2l-fYdBYzNMbWHP7SOUT-qoRXjqvoHXFa5k56UjvIUdl7-Dk35JTL0-ZVcPfVaLU3bC-g-U1ev3kJf9uln1AI9NM4bAkKHWx_5yNZnOGfU_0JgJfM-yiaN-4fFisiDJfJXS-RiEq6ya-sMMy8vj5Wz26HtYTWD-AQbdi6vfl341icFPozhc-lZLxDVqZLQN28Y6qWJrUs2NjEyIVuUqQ8u6UI7SLBSZElbyEBPFLNCCJo7xj7CXT3P3GVhkpdb4L6sc5kJO0TXbWSzTLHXcGt724KAxQjIrGTcSKbUIqcTqwffaLElakZjTLI3bpCimc5WgPROyZxJxD44b4fpKz4od1vZNav9LAkVESJgbSw--Nsu49aieYnI3XRUyiDZlFOsXZRRKYBrnwafSZZp7QQ2ptlbCg3jDmRoBov7eXMnHNwUFuNAcIwOq41vtdo9uffsnfnlRqQfwiuTKQ8iHsLecr9wRQq3lqAW78TBuwf55t9Pp4Wvnotf_1yo21z02SC4I
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6V9FAuiDemBRap7QHV1Pau1-sDQjxapbREEUql3szGu4ZIxE6bRCh_it_IjF9pCOqt13i8WXtm5-GZ-QZg1-cZ2jERuT63sSsio1ydWukKaTg6HFqYtET77MnuufhyEV5swJ-mF4bKKhudWCpqU6T0jfzQV4RMg8GKfD-5dGlqFGVXmxEalVic2sVvDNmm704-I3_3guD4aPCp69ZTBdw0jIKZa2KJNloNdWwCTxsrVWR0GnMtQx3gDrnKcJc2kMM0C0SmhJE8wKAnw3CfpmdxXPcObArqaO3A5sejXv9bo_s5ekvkcPsyoshM8boj0OPqUE8IHdyXb2kO8xbqtvzHJVqnVXu45uSu12r-k7At7eDxfbhXO7DsQyVxD2DD5g9hv18hYC8O2GDZ0DU9YPusv8TGXjyCvGoMzuovhazIGHqgDNk7cmfzcXHFqNGC5lngb4aNLTUmj6bjKVHm85QKcdAvZvV4IaZZXtWxs8m1_2ENUvpjOL8V5jyBTl7k9hmw0Mg4RnWuLAZdVtGaXhbJNEstN5p7Dmy3TEgmFbRHImUsAsrlOvCmYUuS1mjpNLTjV1Jm7blKkJ8J8TMJuQO7LXGz0n_Jdhr-JrWmmCZLuXbgdXsZzzglbnRui3lJg26tDKP4RhqFFBgvOvC0Epl2L_iGlBcr4UC0IkwtAWGMr17JRz9LrHERczRB-Dr2GrG7tvX1R3x-8yO-gq3u4OtZcnbSO92Gu3RTVfq8A53Z1dy-QAdvNnxZnyoG32_7IP8FvjJmZg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9NADLfGkGAviG_CBhzStge0rEkuubs8IIQY1cbQ1IdN6lu45i5QaU26pRXqv8Zfh52vrhTtba-Nc73E9tmO7Z8Bdn2eoR0LpetzG7uhNMrVqRVuKAxHh0OHJq3QPs_E8UX4bRgNN-BP2wtDZZXtmVgd1KZI6Rt5z1eETIPBiuhlTVnE4Kj_aXrl0gQpyrS24zRqETm1i98YvpUfT46Q13tB0P96_uXYbSYMuGkkg5lrYoH2Wo10bAJPGyuUNDqNuRaRDnC3XGW4YxuIUZoFYaZCI3iAAVCGoT9N0uK47j24Lzl6VahLctgFexz9JnK9fSEpRlO86Q30uOrpKeGE--KQJjI_xFMu_3mFdmrVMq65u-tVm_-kbiuL2H8MjxpXln2uZe8JbNj8KewPaizsxQE7X7Z2lQdsnw2WKNmLZ5DXLcJZ882QFRlDX5Qho8fubD4prhm1XNBkC_zNsImlFuVxOSmJMp-nVJKDHjJrBg0xzfK6op1Nb_wPazHTn8PFnbDmBWzmRW5fAYuMiGM82JXF8MsqWtPLpEiz1HKjuefAdseEZFqDfCRCxGFAWV0HPrRsSdIGN53Gd1wmVf6eqwT5mRA_k4g7sNsRtyv9l2yn5W_SnBllspRwB953l1HbKYWjc1vMKxp0cEUk41tpFFJg5OjAy1pkur3gG1JerEIH5IowdQSENr56JR__qlDHw5ijMcLXsdeK3Y2trz_i69sf8R08QPVNvp-cnW7DFt1T10DvwObsem7foKc3G72tVIrBj7vW4b8bhmkt
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+the+anti-tumor+activity+and+mechanisms+of+nuciferine+through+a+network+pharmacology+approach&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%8D%AF%E7%90%86%E5%AD%A6%E6%8A%A5%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Quan+QI+Rui+LI+Hui-ying+LI+Yu-bing+CAO+Ming+BAI+Xiao-jing+FAN+Shu-yan+WANG+Bo+ZHANG+Shao+LI&rft.date=2016-07-01&rft.issn=1671-4083&rft.eissn=1745-7254&rft.issue=7&rft.spage=963&rft.epage=972&rft_id=info:doi/10.1038%2Faps.2016.53&rft.externalDocID=669421302
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F95561A%2F95561A.jpg